Malignant Endocrine Neoplasm — Trials

Malignant Endocrine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 577
Recruiting: 292
Ph III recruiting: 34
Growth YoY: +0.7%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (238)

clinicaltrialsPublishedShowing 301–350 of 909 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02514447	Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy	completed	Phase 1 / Phase 2	123	G1 Therapeutics, Inc.INDUSTRY	8	Sep 25, 2025	clinicaltrials
NCT03041311	Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC	completed	Phase 2	107	G1 Therapeutics, Inc.INDUSTRY	7	Sep 25, 2025	clinicaltrials